Smoking Cessation in Hispanic Construction Workers

NCT ID: NCT02873377

Last Updated: 2019-11-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

134 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-13

Study Completion Date

2018-10-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Construction workers have the highest rate of smoking among all occupations, and are frequently exposed to a wide range of workplace hazards (e.g. toxins), which interact with smoking to increase their health risks. Minority construction workers, in particular, have higher smoking and lower cessation rates compared to other groups, and they generally show lower access and participation in cessation and health promotion services. The number of Hispanic workers employed in the construction industry in the US has tripled in the past decade to 2.6 million (23% of all construction workers). This study will develop, administer, and evaluate a novel smoking cessation program in a hard-to-reach and underserved population of Hispanic male construction workers using using pilot cluster randomized clinical trial (RCT) to test the developed intervention for feasibility and potential efficacy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A two-arm, cluster-randomized controlled trial will be conducted with up to 15 construction sites, selected from one Construction Company in south Florida. Cluster randomization is used with construction site chosen as the unit of allocation because it is most practical in this setting and minimizes the risk of spillover effects from the intervention to the control group. In conjunction with the site's safety manager, the investigators will recruit 9 adult Hispanic construction workers per site (126 total) who smoke ≥5 cigarettes/day in the last year. Participants in the enhanced care will receive one culturally adapted brief face-to-face behavioral counseling session developed in phase 1 and delivered at a lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida quitline (QL), and provision of up to 6 weeks of free NRT. Participants in the standard care will receive fax referral to the Florida QL, and provision of up to 8 weeks of free NRT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Cessation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Study arms will be conducted simultaneously.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Enhanced Care

Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling \& Smoking Quitline Referral. Participants in the "Enhanced Care" intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment.

Group Type EXPERIMENTAL

Nicorette Gum

Intervention Type DRUG

GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)

Nicoderm CQ

Intervention Type DRUG

GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)

Smoking Quitline Referral

Intervention Type OTHER

Fax referral to the State smoking Quitline

Behavioral Smoking Cessation Counseling

Intervention Type BEHAVIORAL

One time face-to-face smoking cessation counseling and follow-up phone call

Standard Care

Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The "Standard Care" group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment.

Group Type ACTIVE_COMPARATOR

Nicorette Gum

Intervention Type DRUG

GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)

Nicoderm CQ

Intervention Type DRUG

GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)

Smoking Quitline Referral

Intervention Type OTHER

Fax referral to the State smoking Quitline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nicorette Gum

GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)

Intervention Type DRUG

Nicoderm CQ

GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)

Intervention Type DRUG

Smoking Quitline Referral

Fax referral to the State smoking Quitline

Intervention Type OTHER

Behavioral Smoking Cessation Counseling

One time face-to-face smoking cessation counseling and follow-up phone call

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NRT NRT Quitline Counseling

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hispanic
* Construction worker
* Have smoked ≥ 5 cigarettes/day in the past year.
* Have access to telephone
* Have no plans to move in the next six months
* Are interested in making a serious quit attempt in the next 30 days
* Have no contraindication to NRT (e.g., history of hypersensitivity to nicotine, recent (past month) myocardial infarction, any history of serious arrhythmias or unstable angina pectoris, chronic dermatological disorder (e.g., psoriasis)).

Exclusion Criteria

* Inability to understand consent procedures
* Not Hispanic
* Not a construction worker
* Haven't smoked ≥ 5 cigarettes/day in the past year.
* No access to telephone
* Has plans to move in the next six months
* Not interested in making a serious quit attempt in the next 30 days
* Has a contraindication to NRT
* Has a generalized chronic dermatological disorder (e.g., psoriasis)
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

University of Miami

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

David Lee, PhD

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David J Lee, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Miami

Taghrid Asfar, MD

Role: STUDY_DIRECTOR

University of Miami

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Building University of Miami

Miami, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Asfar T, Arheart KL, McClure LA, Ruano-Herreria EC, Dietz NA, Ward KD, Caban-Martinez AJ, Samano Martin Del Campo D, Lee DJ. Implementing a Novel Workplace Smoking Cessation Intervention Targeting Hispanic/Latino Construction Workers: A Pilot Cluster Randomized Trial. Health Educ Behav. 2021 Dec;48(6):795-804. doi: 10.1177/1090198120960395. Epub 2020 Oct 16.

Reference Type DERIVED
PMID: 33063570 (View on PubMed)

Asfar T, McClure LA, Arheart KL, Ruano-Herreria EC, Gilford CG Jr, Moore K, Dietz NA, Ward KD, Lee DJ, Caban-Martinez AJ. Integrating Worksite Smoking Cessation Services Into the Construction Sector: Opportunities and Challenges. Health Educ Behav. 2019 Dec;46(6):1024-1034. doi: 10.1177/1090198119866900. Epub 2019 Aug 19.

Reference Type DERIVED
PMID: 31426671 (View on PubMed)

Asfar T, Caban-Martinez AJ, McClure LA, Ruano-Herreria EC, Sierra D, Gilford Clark G Jr, Samano D, Dietz NA, Ward KD, Arheart KL, Lee DJ. A cluster randomized pilot trial of a tailored worksite smoking cessation intervention targeting Hispanic/Latino construction workers: Intervention development and research design. Contemp Clin Trials. 2018 Apr;67:47-55. doi: 10.1016/j.cct.2018.02.007. Epub 2018 Feb 14.

Reference Type DERIVED
PMID: 29454141 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R21CA202993-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

20140019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Overcoming Nicotine Dependence to Enable Quitting
NCT05513872 RECRUITING PHASE1/PHASE2
iCanQuit Smoking Cessation Among Hispanic Adults
NCT06811038 NOT_YET_RECRUITING PHASE3
Smoking Cessation in Hospitalized Smokers
NCT01289275 COMPLETED PHASE4